Indeed, in colorectal cancer cells, the targeting of extracellular VEGF-A with high doses of bevacizumab did not affect cell migration, whereas intracellular VEGF-A depletion significantly impaired migration and ECM invasion. Here, VEGFA is linked to colorectal cancer.